Bovine papillomavirus type 1 is one of the aetiological agents of equine sarcoids. The viral major oncoprotein E5 is expressed in virtually all sarcoids, sarcoid cell lines and in vitro-transformed equine fibroblasts. To ascertain whether E5 behaves in equine cells as it does in bovine cells, we introduced the E5 open reading frame into fetal equine fibroblasts (EqPalF). As observed in primary bovine fibroblasts (BoPalF), E5 by itself could not immortalize EqPalF and an immortalizing gene, such as human telomerase (hTERT/hT), was required for the cells to survive selection. The EqPalF-hT-1E5 cells were morphologically transformed, elongated with many pseudopodia and capable of forming foci. Equine major histocompatibility complex class I (MHC I) was inhibited in these cells at least at two levels: transcription of MHC I heavy chain was inhibited and the MHC I complex was retained in the Golgi apparatus and prevented from reaching the cell surface. We conclude that, as in bovine cells and tumours, E5 is a player in the transformation of equine cells and the induction of sarcoids, and a potential major cause of MHC I downregulation and hence poor immune clearance of tumour cells.
INTRODUCTION
The equine sarcoid is a fibroblastic tumour induced by bovine papillomavirus type 1 (BPV-1) and, more rarely, type 2. Infection of equids by BPV is the first documented case of the ability of a papillomavirus to break the species barrier. BPV-1 infection differs in bovids and equids. In cattle, BPV-1 induces fibropapillomas, benign tumours with both an epithelial and a fibroblastic component that are productive for infective viral progeny and undergo regression after a number of months due to a cell-mediated immune response. In equids, the sarcoids can have different clinical presentation, from verrucous to fibroblastic to malignant, the latter spreading along the lymphatics (reviewed by Knottenbelt, 2005) . Sarcoids are believed to be non-productive for progeny virus, although virus-like particles have been observed recently in sarcoids (Brandt et al., 2008) . Sarcoids rarely regress spontaneously and often recrudesce after treatment .
Little is known about how infection with BPV-1 in equine fibroblasts contributes to the pathogenesis of sarcoids, but certain facets have begun to emerge (Nasir et al., 2007; Yuan et al., 2008a) . BPV-1 induces upregulation of inflammatory cytokines, inhibitors of apoptosis and promoters of cell motility and invasion, and downregulation of components of both the adaptive and the innate immune response (Yuan et al., 2008b ). E5, the major oncoprotein of BPV-1, is expressed in virtually all sarcoids, sarcoid cell lines and equine fibroblasts transformed in vitro by BPV-1 (Borzacchiello et al., 2008; Chambers et al., 2003; Yuan et al., 2007 Yuan et al., , 2008a . We have shown that the E5 oncoprotein is responsible for the inhibition of major histocompatibility complex class I (MHC 1) in bovine cells and bovine papillomas (Araibi et al., 2004; Ashrafi et al., 2002; Marchetti et al., 2002 Marchetti et al., , 2006 . To ascertain whether E5 also inhibits MHC I in the case of equine sarcoids, we established stable equine cell lines expressing BPV-1 E5.
cyanate (FITC)-conjugated antibody, appropriate for flow cytometry (Sigma). mAb HA.11 (Cambridge Bioscience) is directed against the haemagglutinin (HA) epitope tag of E5.
Plasmids. The complete BPV-1 E5 open reading frame (ORF) and the E5 ORF with a premature stop codon at residue 32, both tagged with the HA epitope at the ORF 59 end, were subcloned from equivalent pZipneo recombinant plasmids (O'Brien et al., 1999) into pcDNA3, giving rise to pcDNA3.1HA1E5 (1E5) and pcDNA3. 1HA1E5T (1E5T), respectively.
Plasmid pcineohTERT has the human telomerase (hTERT) reverse transcriptase gene cloned in the pcineo plasmid. The original pBabehTERT plasmid was a kind gift of Professor Nicol Keith, University of Glasgow.
Plasmids pcDNA3-B2 and pcDNA3-B4 contain the cDNAs for equine class I alleles B2 and B4, respectively (GenBank accession numbers X79891 and X79892, respectively), inserted in the EcoRI site of pcDNA3.
Cell lines. Primary equine fibroblasts (EqPalF) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum (both from Invitrogen Life Technologies). Stable transfectants expressing either BPV-1 E5 and hTERT or hTERT alone were produced by co-transfection with pcDNA3.1HA1E5 and pcineohTERT, or pcineo-hTERT and pcDNA3 empty vector, with Nucleofector (Amaxa GmbH), using the kit provided and following the instructions supplied by the manufacturer, and maintained under G418 selection. These cells were designated EqPalF-hT-1E5 and EqPalF-hT-pc, respectively. The BPV-1 E5-expressing cell line ES01, a sarcoid cell line, has been described previously (Yuan et al., 2008a, b) .
Real-time quantitative RT-PCR (q-RT-PCR). RNA was extracted from EqPalF cells by using an RNeasy Mini kit (Qiagen), and residual DNA was inactivated by using DNase I treatment (Invitrogen) prior to RT-PCR. The reverse transcription was primed with random primers (Promega) at a concentration of 0.2 mg in a 12 ml reaction mixture. Following the instructions of the supplier, 20 ml Moloney murine leukemia virus (M-MLV) Reverse Transcriptase kit (Invitrogen) were added, containing 56 First-Strand Buffer, 0.1 M dithiothreitol, 40 U RNaseOUT recombinant RNase inhibitor and 200 U M-MLV reverse transcriptase. The equine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (GenBank accession no. AF157626) and the equine MHC I heavy chain mRNA (accession no. X71809) were chosen as endogenous control and as target, respectively. Primers and probes were designed by using Primer Express (v1.7; Perkin-Elmer).
cDNA was amplified in triplicate for GAPDH with the following primers: GAPDH-F, 59-GGTGGAGCCAAAAGGGTCAT-39; GAPD-H-R, 59-TTCACGCCCATCACAAACAT-39; and the TaqMan probe FAM-ATCTCTGCTCCTTCTGCTGATGCCCC-TAMRA. ELA heavychain cDNA was amplified with the following primers: EqMHC-F, 59-AGGACAACGCACAGGCTTTC-39; EqMHC-R, 59-GGCCTCGC-TCTGGTTGTAGT-39; and the TaqMan probe FAM-AGCCTGAA-CAACCTGCGCGGC-TAMRA.
Primers were used at a concentration of 600 nM each in a 25 ml reaction that contained 12.5 ml TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) and the detection probe at a concentration of 250 nM. The thermal-cycling conditions were 2 min at 50 uC and 10 min at 95 uC, followed by 40 cycles of 95 uC for 15 s and 60 uC for 1 min. All reactions were performed in a model 7500 sequence detector (Applied Biosystems).
Immunofluorescence. Cells were grown until 80 % confluent in single-well chamber slides. After removal of medium, cells were washed twice with serum-free DMEM, 25 mM HEPES (DMEM-H).
Cells were then washed twice with PBS and fixed in fixing solution (19 ml PBS, 1 ml 37 % formaldehyde and 0.4 g sucrose) for 10 min at room temperature (RT). Cells were incubated in permeabilizing solution (19 ml PBS, 1 ml 10 % NP-40 and 0.4 g sucrose) at RT for 10 min and washed as above, then incubated with anti-ELA mouse mAb H58A for 1 h at RT, and then with anti-mouse IgG (Fabspecific)-FITC conjugate (Sigma) at 4 uC for 1 h in the dark. Following three final washes with PBS, the slides were mounted in Citifluor (Citifluor Ltd) and analysed with a Leica TCS SP2 fluorescence confocal microscope.
Flow cytometry. Flow cytometry for MHC I in equine fibroblasts was performed as described by Marchetti et al. (2006) . Briefly, for the detection of surface MHC I, cells were incubated for 30 min at 4 uC with H58A (1 : 100) and then with the secondary goat anti-mouse IgG (Fab-specific) FITC-conjugated antibody. For the detection of intracellular MHC I, the cells were permeabilized with 0.1 % saponin in PBS with 1 % BSA (New England Biolabs) for 30 min at RT, and stained as described above. All samples were examined in a Beckman Coulter EPICS Elite analyser equipped with an ion argon laser with 15 mV excitation at 488 nm. The data were analysed by using the accompanying EXPO 2 software.
In vitro transcription/translation and co-immunoprecipitation.
In vitro transcription/translation reactions were performed essentially as described by Marchetti et al. (2006) , using the TNT T7 Quick Coupled Transcription/Translation system (Promega) in the presence of Redivue L-[
35 S]methionine (Amersham Pharmacia Biotech), following the manufacturer's instructions. Briefly, 1 mg pcDNA3.1HA1E5, pcDNA3.1HA1E5T, pcDNA3-B2 or pcDNA3-B4 was mixed in a 50 ml reaction containing TNT mix in the presence of canine microsomal membranes (Promega) at 30 uC for 1.5 h. Half of each transcription/translation reaction product was immunoprecipitated with either a 1 : 2 dilution of MAC 291 or a 1 : 10 dilution of H58A. The other half of each reaction was left without antibody as a negative control. For co-immunoprecipitation, the individual transcription/translation products were mixed in equivalent amounts and immunoprecipitated with double the amount of either antibody. For competition experiments, the transcribed/translated unlabelled product of 1E5T was added to labelled B2 or B4 for 1 h before the addition of labelled 1E5 as described above. After incubation overnight at 4 uC and addition of protein G-Sepharose bead suspension (Sigma), the complexes were electrophoresed in 4-12 % NuPAGE gels (Invitrogen). Gels were fixed with glacial acetic acid and methanol, incubated for 15 min in Amplify Fluorographic reagent (Amersham Pharmacia Biotech), dried and exposed for autoradiography at 270 uC overnight or exposed on a screen for quantification on a Storm 840 apparatus using the accompanying IMAGEQUANT v5.2 software.
RESULTS AND DISCUSSION
Whilst the full genome of BPV-1 can immortalize and transform EqPalF (Yuan et al., 2008a) , several attempts to establish EqPalF cells harbouring the BPV-1 E5 gene and expressing E5 failed, as the cells did not survive selection and died (data not shown). The same behaviour was observed in primary bovine fibroblast (BoPalF) cells transfected with BPV E5, where the E6 protein of HPV-16 had to be added to immortalize the cells and allow the study of E5 functions (Pennie et al., 1993) . To see whether cell immortalization would allow the establishment of EqPalF expressing E5, we co-transfected EqPalF with an hTERT-expressing plasmid and empty pcDNA vector as control, or with hTERT-and BPV-1 E5-expressing plasmids. Cell lines were established both with hTERT (EqPalF-hT-pc) and with hTERT and E5 (EqPalF-hT-1E5). Both cell lines expressed hTERT at approximately equal levels, whereas only EqPalF-hT-1E5 cells expressed E5, as assessed by RT-PCR (data not shown). Whilst the parental EqPalF cells senesced and died, the EqPalF-hT-pc and EqPalF-hT-1E5 cells continued to proliferate at essentially the same rate (Fig. 1) . It is thus clear that BPV E5 cannot induce immortalization in either BoPalF or EqPalF and needs an additional immortalization event for the establishment of stable cell lines.
As both the EqPalF-hT-pc and the EqPalF-hT-1E5 cell lines are polyclonal, and therefore represent a mixed population, the effects observed here and in the subsequent experiments cannot be due to clonal variation. To see whether E5 was able to transform EqPalF morphologically, the cells were analysed under a light microscope. The EqPalF-hT-pc cells showed the typical fibroblast morphology and tended to stop growing after reaching confluence. In contrast, EqPalF-hT-1E5 cells formed foci of non-contact-inhibited cells and the cells were elongated with long and numerous pseudopodia (Fig. 2) . Therefore, BPV-1 E5 does transform EqPalF morphologically as it does BoPalF in terms of focus formation and cell shape (Tsirimonaki et al., 2006) . However, in contrast to BoPalF-E5 cells, the EqPalF-hT-1E5 cells do not form colonies in semi-solid media (data not shown). As EqPalF expressing the three BPV-1 E5, E6 and E7 oncoproteins are capable of growing in an anchorage-independent fashion (Yuan et al., 2008a) , it can be deduced that either E6 and/or E7 is responsible for this characteristic.
One notable feature of E5-expressing BoPalF cells is the profound and irreversible downregulation of the bovine MHC I (BoLA). MHC I downregulation in bovine cells takes place at different levels: inhibition of transcription of the heavy-chain gene, interaction with and degradation of the heavy-chain peptide and retention of the BoLA complex in the Golgi apparatus Marchetti et al., 2002 Marchetti et al., , 2006 . To see whether E5 would cause the same dramatic effect on equine MHC I (ELA), we first assessed transcription of the heavy-chain gene by quantitative RT-PCR, as described previously (Yuan et al., 2008a) . Transcription of the heavy chain was inhibited in EqPalF-hT-1E5 cells compared with EqPalF-hT-pc cells (Fig. 3) , showing that E5 can also inhibit the ELA transcriptional promoter. There was no change in the levels of GAPDH mRNA between the cell lines (data not shown). It still remains to be clarified how E5, a membrane-associated protein, can influence the transcription activity of the promoters of several genes (Grindlay et al., 2005; Marchetti et al., 2006) , but it is reasonable to 
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assume that E5 initiates a signal cascade that ultimately results in activation or repression of transcription. It has been shown that E5 activates src, fos, ERK, PDGF-R and PI3K (Suprynowicz et al., 2006) . Any one of these pathways can contribute to transcriptional regulation.
We could not analyse the levels of heavy-chain protein in EqPalF cells, as the available anti-ELA antibodies did not perform well in Western blots. The antibodies were appropriate, however, for immunofluorescence, flow cytometry and immunoprecipitation. Immunofluorescence showed that, while in parental EqPalF and in EqPalF-hTpc, ELA was detectable in the Golgi apparatus, the secretory system and importantly the cell surface, in EqPalF-hT-1E5, ELA was mainly restricted to the Golgi apparatus (Fig. 4a) .
The levels of surface ELA were also measured by flow cytometry in EqPalF-hT-pc and EqPalF-hT-1E5 cells, along with parental EqPalF and ES01a sarcoid cells as controls (Yuan et al., 2008b) . It was clear that the EqPalF-hT-1E5 cells had a reduced amount of surface MHC I (approximately 60 % of control; Fig. 4b ), thus confirming that the reduction in MHC I (heavy-chain) RNA indeed results in a downregulation of the MHC I complex, in complete agreement with the results obtained in bovine cells. One point has to be noted: EqPalF-hT-pc cells have approximately twice as much surface MHC I as the parental EqPalF cells. This observation has been repeated numerous times, but the reason for this is not known. How expression of hTERT might influence expression of MHC I requires further analysis, beyond the scope of the present work. However, despite the increased expression level of surface MHC I in cells expressing hTERT, it is clear that E5 downregulates surface MHC I to approximately the same extent as surface MHC I is downregulated in sarcoid cells (Fig. 4b) (Yuan et al., 2008b) .
We have shown that retention of the residual BoLA in the Golgi apparatus of BoPalF-E5 cells is due to two factors: impeded acidification of the Golgi and the interaction between E5 and the MHC I heavy chain . To see whether the interaction between E5 and the heavy chain was also taking place in the case of ELA, we performed co-immunoprecipitation experiments between in vitro-transcribed/translated BPV-1 E5 and two alleles of ELA, B2 and B4 (Ellis et al., 1995) . E5 interacted with both B2 and B4, and the interacting peptides could be co-immunoprecipitated either with an anti-HA antibody (HA-1E5) or with MAC 291 (B2) and H58A (B4) antibodies (Fig. 5a ). The interaction between BPV E5 and BoLA heavy chain is mediated by the Cterminal tail of E5 , and this is also the case for BPV-1 E5 and ELA heavy chain. E5T, a deletion mutant lacking the C-terminus tail, did not bind to B2 and could not compete with full-length E5 for B2 binding (Fig.  5b) . The same results were obtained with E5 and B4 (data not shown). In conclusion, BPV-1 E5 behaves in equine cells as it does in bovine cells with respect to cell transformation without concomitant immortalization, and in the downregulation of MHC class I. We propose that E5 acts as the main oncoprotein of BPV-1 in equids as it does in cattle, and that the lack of spontaneous regression of sarcoids, their persistence and recurrence are probably due to E5-mediated downregulation of ELA and therefore escape from immune recognition. Sarcoid regression can be induced by vaccination (Ashrafi et al., 2008; Hallamaa et al., 2005; Mattil-Fritz et al., 2008) , indicating that immune evasion can be overcome, but whether and what type of immune cells are involved are not known.
